Skip to main content
    C

    Castle Biosciences Inc (CSTL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $33.79
    -0.71 (-2.06%)

    Market Cap: $1.04B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Castle Biosciences Inc (CSTL) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Castle Biosciences (CSTL) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Castle Biosciences reported EPS of -$0.13, above the -$0.38 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    79%(23/29)
    Avg Surprise
    +98.02%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.16
    Range-$0.39 - $0.00
    12 analysts
    Revenue Consensus
    $104.66M
    Range$98.10M - $112.56M
    12 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.31
    Range-$0.46 - -$0.18
    6 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.42+25.8%
    60d ago-$0.42+25.8%
    30d ago-$0.40+23.5%
    7d ago-$0.39+21.2%
    Current-$0.31
    Revenue Consensus
    $100.99M
    Range$92.20M - $107.20M
    8 analysts

    Next Report

    CSTL has an expected report date of Feb 22, 2027.

    CSTL Earnings Call

    The latest CSTL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 29 quarters below that had an estimate, CSTL beat 23, missed 5 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $102.89M, up 23.9% from $83.04M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.13-$0.38-$0.42 - -$0.25+65.79%BeatN/A102 up, 0 downNov 5, 2026$102.89M
    Jun 30, 2026-$0.07-$0.44-$0.53 - -$0.30+84.09%Beat-146.7%92 up, 6 downJul 30, 2026$103.55M
    Mar 31, 2026-$0.49-$0.49-$0.58 - -$0.290.00%In lineN/A8N/AMay 6, 2026$83.68M
    Dec 31, 2025-$0.08-$0.23-$0.38 - -$0.07+65.22%Beat-125.0%84 up, 0 downFeb 26, 2026$87.01M
    Sep 30, 2025-$0.02-$0.51-$0.65 - -$0.34+96.08%Beat-125.0%72 up, 0 downNov 3, 2025$83.04M
    Jun 30, 2025$0.15-$0.50-$0.64 - -$0.36+130.00%Beat-51.6%70 up, 2 downAug 4, 2025$86.19M
    Mar 31, 2025-$0.90-$0.07-$0.31 - $0.10N/AN/AN/A71 up, 1 downMay 5, 2025$87.99M
    Dec 31, 2024$0.32$0.04-$0.12 - $0.16+700.00%BeatN/A72 up, 1 downFeb 27, 2025$86.31M
    Sep 30, 2024$0.08$0.01-$0.50 - $0.19+700.00%BeatN/A73 up, 0 downNov 4, 2024$85.78M
    Jun 30, 2024$0.31-$0.24-$0.46 - -$0.10+229.17%BeatN/A91 up, 0 downAug 5, 2024$87.00M
    Mar 31, 2024-$0.09-$0.31-$0.57 - -$0.17+70.97%BeatN/A90 up, 0 downMay 2, 2024$72.97M
    Dec 31, 2023-$0.10-$0.54-$0.95 - -$0.17+81.48%BeatN/A82 up, 0 downFeb 28, 2024$66.12M
    Sep 30, 2023-$0.26-$0.73-$1.03 - -$0.47+64.38%BeatN/A80 up, 0 downNov 2, 2023$61.49M
    Jun 30, 2023-$0.70-$0.91-$1.11 - -$0.67+23.08%BeatN/A80 up, 0 downAug 2, 2023$50.14M
    Mar 31, 2023-$1.10-$0.89-$1.02 - -$0.74-23.60%MissN/A80 up, 0 downMay 3, 2023$42.04M
    Dec 31, 2022-$0.78-$0.84-$0.95 - -$0.78+7.14%BeatN/A81 up, 0 downFeb 28, 2023$38.34M
    Sep 30, 2022-$0.77-$0.97-$1.06 - -$0.41+20.62%BeatN/A70 up, 1 downNov 2, 2022$37.01M
    Jun 30, 2022-$0.06-$0.80-$0.89 - -$0.52+92.50%BeatN/A71 up, 0 downAug 8, 2022$34.84M
    Mar 31, 2022-$0.97-$0.74-$0.76 - -$0.57-31.08%MissN/A70 up, 0 downMay 9, 2022$26.85M
    Dec 31, 2021-$0.25-$0.47-$0.52 - -$0.39+46.81%BeatN/A70 up, 0 downFeb 28, 2022$25.04M
    Sep 30, 2021-$0.47-$0.37-$0.49 - -$0.32-27.03%MissN/A6N/ANov 8, 2021$23.48M
    Jun 30, 2021-$0.35-$0.39-$0.47 - -$0.27+10.26%BeatN/A5N/AAug 9, 2021$22.76M
    Mar 31, 2021-$0.17-$0.18-$0.36 - -$0.18+5.56%Beat-666.7%6N/AMay 10, 2021$22.81M
    Dec 31, 2020-$0.17-$0.12-$0.18 - -$0.05-41.67%Miss-254.5%5N/AMar 8, 2021$17.30M
    Sep 30, 2020-$0.23-$0.15-$0.19 - $0.04-53.33%Miss-1250.0%4N/ANov 9, 2020$15.22M
    Jun 30, 2020-$0.08-$0.44-$0.50 - -$0.26+81.82%BeatN/A4N/AAug 10, 2020$12.71M
    Mar 31, 2020$0.03-$0.05-$0.24 - -$0.05+160.00%BeatN/A4N/AMay 11, 2020$17.42M
    Dec 31, 2019$0.11-$0.20-$0.23 - -$0.18+155.00%BeatN/A3N/AMar 10, 2020$17.63M
    Sep 30, 2019$0.02-$0.30-$0.31 - -$0.29+106.67%BeatN/A4N/ANov 11, 2019$14.77M
    Jun 30, 2019-$1.05-$1.36-$3.07 - -$0.38+22.79%BeatN/A4N/AJul 26, 2019$10.74M
    Mar 31, 2019-$1.22N/AN/AN/AN/AN/AN/AN/AMay 29, 2019$8.72M
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.85, after $0.62 the year before. It was -$2.14 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.85-237.1%
    Dec 31, 2024$0.62N/A
    Dec 31, 2023-$2.16N/A
    Dec 31, 2022-$2.58N/A
    Dec 31, 2021-$1.24N/A
    Dec 31, 2020-$0.45N/A
    Dec 31, 2019-$2.14N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,500 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,46113
    2026Q2Jun 30, 20265,09813
    2026Q1Mar 31, 20264,36210
    2025Q4Dec 31, 20256,3209
    2025Q3Sep 30, 20255,39811
    2025Q2Jun 30, 20255,90011
    2025Q1Mar 31, 20256,28014
    2024Q4Dec 31, 20246,28712

    2026Q3 Earnings Call

    Opening remarks

    Camilla Zuckero Vice President, Investor Relations and Corporate Affairs Thank you, operator. Good afternoon, everyone. Welcome to Castle Biosciences Third Quarter 2026 Results Conference Call. Joining me today are Castle's Founder, President and Chief Executive Officer, Derek Maetzold, and Chief Financial Officer, Frank Stokes. Information recorded on this call speaks only as of today, November 5, 2026. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately three weeks following the conclusion of the call. Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements, including statements about expected addressable markets; statements containing projections regarding future events or our future financial or operational results and performance, including our anticipated 2026 total revenue, test report volume growth guidance and positive adjusted EBITDA for the fourth quarter, full year 2026 and full year 2027; and the impact of our investments in growth initiatives, including our ability to achieve long-term growth and drive stockholder value. Forward-looking statements are based upon current expectations and involve inherent risks and uncertainties, and there can be no assurances that the results contemplated in these statements will be realized. A number of factors and risks could cause actual results to differ materially from those contained in these forward-looking statements. Please refer to the risk factors in our most recent SEC filings for more information. These forward-looking statements speak only as of today, and we assume no obligation to update or revise these forward-looking statements as circumstances change. In addition, some of the information discussed today includes non-GAAP financial measures, such as adjusted revenue, adjusted gross margin and adjusted EBITDA, that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the Investor Relations page of the company's website. I will now turn the call over to Derek.

    Derek Maetzold Founder, President and Chief Executive Officer Thank you, Camilla, and good afternoon, everyone. Our team closed out a very successful third quarter, reflecting our focused execution and disciplined expense management, underscored by the clinical value our tests provide to clinicians and their patients. We delivered revenue of $102.9 million, 24% growth compared to the third quarter of 2025, primarily driven by TissueCypher test report volume, which grew by 47% compared to the third quarter of 2025.

    Frequently Asked Questions About CSTL

    When is Castle Biosciences's next earnings date?

    Castle Biosciences's next earnings report is expected for Feb 22, 2027.

    Did CSTL beat earnings estimates last quarter?

    Yes. Castle Biosciences reported EPS of -$0.13 for the quarter ended Sep 30, 2026, above the -$0.38 estimate, a 65.79% surprise.

    What EPS do analysts expect from CSTL next quarter?

    The consensus EPS estimate for Castle Biosciences for the quarter ending Dec 31, 2026 is -$0.16 from 12 analysts, with estimates from -$0.39 to $0.00.

    How often does CSTL beat earnings estimates?

    Castle Biosciences beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +230.15%.